Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD0156 + Miransertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0156 | AZD-0156 | ATM Inhibitor 13 | AZD0156 is an inhibitor of ataxia telangiectasia mutated (ATM) kinase and radiosensitizer, which leads to defective DNA damage repair and apoptosis in tumor cells (PMID: 31534013). | |
Miransertib | ARQ-092|ARQ092|ARQ 092 | Akt Inhibitor (Pan) 21 | Miransertib (ARQ092) is a pan-AKT inhibitor, resulting in inhibition of the PI3K/AKT signaling pathway and cell proliferation (PMID: 26469692, PMID: 31058421). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | breast cancer | sensitive | AZD0156 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, AZD0156 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 32439931). | 32439931 |
PIK3CA K111N | breast cancer | sensitive | AZD0156 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, AZD0156 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|